Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $9.5
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $11.5 to $9.5.
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $11.5 to $9.5.